Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
TRDA
Strong SellSinkerEntrada Therapeutics, Inc. · Healthcare · United States · $273M · Avg Vol: $2M/d
COMPANY DESCRIPTION
Entrada Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing intracellular biologics using its proprietary Endosomal Escape Vehicle (EEV™) platform. The company aims to deliver therapeutics directly into the cytoplasm of cells, addressing a wide range of diseases that are currently untreatable by conventional biologics. Its innovative EEV platform provides a significant competitive differentiator by enabling access to novel intracellular drug targets.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 129.0M | 210.8M | 25.4M | -55.6% | 4.7M | 13.9M | 22.9M | -5.2% |
| EPS | -3.02 | -0.20 | 1.76 | -3.47 | — | -3.96 | -3.70 | -2.98 | — |
| Shares | 31.4M | 33.4M | 37.6M | 38.3M | +21.9% | 38.9M | — | — | — |
| Debt | 25.9M | 68.2M | 59.2M | 50.9M | 25.2% | 48.5M | — | — | — |
| Equity | 212.6M | 242.4M | 428.7M | 306.1M | 12.9% | — | — | — | — |
| Op CF | -93.8M | 139.8M | -41.6M | -128.5M | — | -134.7M | — | — | — |
| Inv CF | -148.7M | -138.4M | -27.8M | 116.8M | — | — | — | — | — |
| Fin CF | 0.5M | 21.0M | 103.0M | 0.9M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of TRDA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| TRDA | Entrada Therapeutics, Inc.(you) | $273M | 10 | Strong Sell |
| AVXL | Anavex Life Sciences Corp. | $277M | 9 | Strong Sell |
| CAMP | CAMP4 THERAPEUTICS CORPORATION | $260M | 10 | Strong Sell |
| SRZN | Surrozen, Inc. | $264M | 9 | Strong Sell |
| RNAC | Cartesian Therapeutics, Inc. | $290M | 12 | Strong Sell |
| IVVD | Invivyd, Inc. | $284M | 12 | Strong Sell |
| TARA | Protara Therapeutics, Inc. | $226M | 9 | Strong Sell |
| RNA | Atrium Therapeutics, Inc. | $233M | 11 | Strong Sell |
| LCTX | Lineage Cell Therapeutics, Inc. | $281M | 5 | Strong Sell |
| STRO | Sutro Biopharma, Inc. | $339M | 9 | Strong Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.3%